Quest Diagnostics Incorporated (DGX) Income Statement

The deceleration from mid-teens to ~10% growth appears consistent with the normalization of post-pandemic testing volumes rather than share loss, since the absolute revenue base has expanded by roughly $700M over the period. Investors should treat the current 10% rate as the more sustainable run-rate, since the 15% prints in 2025 likely embedded easy year-over-year comparisons. Growth durability now hinges on whether advanced diagnostics and hospital lab outsourcing can offset the maturing routine testing base.

The persistence of the mid-33% gross margin despite inflationary labor and courier costs implies pricing has largely kept pace with input inflation, which is encouraging for a business exposed to PAMA-driven reimbursement resets. The structural gap versus LabCorp may reflect differences in test menu mix and the degree to which lower-margin pass-through work is consolidated in reported revenue. The 60bp sequential drift from 34.2% in 2025Q2 to 33.6% in 2026Q3 warrants monitoring as a possible early signal of mix or pricing fatigue rather than a one-off.

Because operating income rose from $355M to $479M over the period while SG&A intensity was unchanged, the entire margin gain traces to gross profit expansion, which is a lower-quality form of operating leverage if reimbursement tightens. Absolute SG&A grew 29% versus 29% revenue growth, indicating management has sized corporate overhead to the top line rather than leveraging it. Any claim that cost programs are driving earnings should therefore be tested against the SG&A-to-sales ratio, which has so far not improved.

Some of the sequential step-up appears seasonal, since Q1 gross margins printed 32.5% in both 2025 and 2026, so the durability of the inflection should be judged on the year-over-year comparison, where operating margin improved from 15.9% to 15.1% — a mild decline. What is more notable is that operating income has now held above $450M for two consecutive quarters versus a prior $330M-$440M range, suggesting the earnings floor has reset higher. This reset may reflect a favorable shift in test mix toward advanced diagnostics, though the reported data alone cannot isolate that driver.